RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Eurofins-Cerep - Stock

Eurofins-Cerep Stocks 2024

Eurofins-Cerep Stocks

5,040

Ticker

ALECR.PA

ISIN

FR0013256518

WKN

A2DT0B

In 2024, Eurofins-Cerep had 5,040 outstanding stocks, a 0% change from the 5,040 stocks in the previous year.

The Eurofins-Cerep Stocks history

YEARNUMBER OF STOCKS (undefined EUR)
20225.04
20215.04
20205.04
20195.04
20185.04
20175.04
20165.04
20155.04
20145.04
201310
201210
201110
201010
200910
200810
200710
200610
2005-
2004-
2003-

Eurofins-Cerep shares outstanding

  • 3 years

  • 5 years

  • 10 years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Eurofins-Cerep earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Eurofins-Cerep's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Eurofins-Cerep’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Eurofins-Cerep's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Eurofins-Cerep Aktienanalyse

What does Eurofins-Cerep do?

Eurofins-Cerep SA is a globally renowned biotechnology company that was founded in 1993. With its headquarters in Paris, France, the company operates over 47 locations worldwide and employs over 45,000 employees. The company specializes in the development and commercialization of innovative biological technologies for use in the pharmaceutical industry. Eurofins-Cerep focuses on the discovery of new drugs for the treatment of diseases such as cancer, Alzheimer's, Parkinson's, and diabetes. The business model of Eurofins-Cerep is based on three pillars: services, product sales, and research and development offerings. Under the "services" division, the company offers extensive pharmacological and biological testing and screening procedures for drug compounds to its customers. Eurofins-Cerep has a wide range of assays and tests that allow customers to assess and optimize the efficacy and safety of their drug compounds. The "product sales" division includes the manufacturing and distribution of over 1,000 different biological reagents, antibodies, and other products for biomedical research. The company specializes in producing reagents used in drug development, such as G-protein coupled receptors (GPCRs). The third pillar of Eurofins-Cerep's business model consists of research and development services for customers and partners. The company supports customers in identifying new drug compounds and developing drug candidates up to market approval. The company has various divisions, including the Cerep division, which specializes in the evaluation of potential drug candidates and associated toxicology. The Eurofins Pharma Discovery Services division offers advanced drug optimization and screening services by providing customized approaches to drug development. The Eurofins BioPharma Services division is a leading provider of complete solutions in the pharmaceutical development and GxP laboratories. The company is also active in other areas such as the environment and the food industry. Eurofins-Cerep has made several acquisitions in the past, including the acquisition of XDS Laboratories, a leading provider of clinical laboratory services, and EAG Laboratories, a highly specialized analysis and testing service unit. Overall, Eurofins-Cerep SA has achieved numerous milestones in the past 28 years and has become one of the world's leading providers of biological screening and analysis technologies. The company remains committed to offering its customers innovative biological technologies and maintaining its reputation as a reliable partner in the pharmaceutical industry. Eurofins-Cerep ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Eurofins-Cerep's Shares Outstanding

Eurofins-Cerep's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Eurofins-Cerep’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Eurofins-Cerep’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Eurofins-Cerep’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Eurofins-Cerep Stock

How many stocks are there of Eurofins-Cerep?

The current number of stocks of Eurofins-Cerep is 5,040 undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Eurofins-Cerep are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Eurofins-Cerep evolved in recent years?

The number of shares of Eurofins-Cerep has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Eurofins-Cerep as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Eurofins-Cerep?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Eurofins-Cerep pay?

Over the past 12 months, Eurofins-Cerep paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Eurofins-Cerep is expected to pay a dividend of 0 EUR.

What is the dividend yield of Eurofins-Cerep?

The current dividend yield of Eurofins-Cerep is .

When does Eurofins-Cerep pay dividends?

Eurofins-Cerep pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Eurofins-Cerep?

Eurofins-Cerep paid dividends every year for the past 0 years.

What is the dividend of Eurofins-Cerep?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Eurofins-Cerep located?

Eurofins-Cerep is assigned to the 'Health' sector.

Wann musste ich die Aktien von Eurofins-Cerep kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Eurofins-Cerep from 6/26/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 6/26/2024.

When did Eurofins-Cerep pay the last dividend?

The last dividend was paid out on 6/26/2024.

What was the dividend of Eurofins-Cerep in the year 2023?

In the year 2023, Eurofins-Cerep distributed 0 EUR as dividends.

In which currency does Eurofins-Cerep pay out the dividend?

The dividends of Eurofins-Cerep are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Eurofins-Cerep

Our stock analysis for Eurofins-Cerep Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Eurofins-Cerep Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.